86933-74-6

Basic information

• Product Name: NEUROKININ A
• Synonyms: ALPHA-NEUROKININ;HKTDSFVGLM-NH2;HIS-LYS-THR-ASP-SER-PHE-VAL-GLY-LEU-MET-NH2;H-HIS-LYS-THR-ASP-SER-PHE-VAL-GLY-LEU-MET-NH2;SUBSTANCE K (HUMAN, PORCINE, RAT, MOUSE);SUBSTANCE K;NKA;NEUROKININ A
• CAS NO: 86933-74-6
• Molecular Formula: C₅₀H₈₀N₁₄O₁₄S
• Molecular Weight: 1133.32
• Product Categories: Tachykinin receptor;Peptide Receptors;peptide
• Mol File: 86933-74-6.mol

Chemical Properties

• Boiling Point: 1610.7 °C at 760 mmHg
• Flash Point: 927.9 °C
• Appearance: White to off-white lyophilized solid
• Density: 1.305 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.58
• Storage Temp.: −20°C
• PKA: 4.17±0.10(Predicted)
• Water Solubility: Soluble in water at 1mg/ml
• CAS DataBase Reference: NEUROKININ A(CAS DataBase Reference)
• NIST Chemistry Reference: NEUROKININ A(86933-74-6)
• EPA Substance Registry System: NEUROKININ A(86933-74-6)

Safety Data

• WGK Germany: 3
• RTECS: PC4360090
• F: 10-21
• Hazardous Substances Data: 86933-74-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Neurokinin A is used as a therapeutic agent for various conditions, including pain, inflammation, and gastrointestinal disorders. It modulates the activity of the NK-2R receptor, which plays a crucial role in the transmission of pain signals and the regulation of smooth muscle contractions.
Used in Research Applications:
Neurokinin A is used as a research tool to study the physiological functions and mechanisms of action of the tachykinin family of peptides and their receptors. It helps researchers understand the role of neurokinin A in various physiological processes, such as neurotransmission, neuromodulation, and neuroinflammation.
Used in Drug Development:
Neurokinin A is used in the development of new drugs targeting the NK-2R receptor for the treatment of various disorders, such as irritable bowel syndrome, chronic cough, and migraine. By modulating the activity of neurokinin A and its receptor, these drugs aim to provide effective relief from symptoms and improve the quality of life for patients.

Biochem/physiol Actions

Neurokinin A improves the multiplication and paracrine ability of stem cells acquired from adipose in vitro. It participates in the movement of several organ tracts, triggers glandular secretion and controls autonomic reflexes. Neurokinin A plays an important role in neuroimmune and systemic autoimmune/inflammatory conditions like multiple sclerosis (MS), rheumatoid arthritis, inflammatory bowel disease and also in infections and cancer.

InChI:InChI=1/C50H80N14O14S/c1-26(2)18-34(45(73)58-32(42(53)70)15-17-79-6)57-38(67)23-55-49(77)40(27(3)4)63-47(75)35(19-29-12-8-7-9-13-29)60-48(76)37(24-65)62-46(74)36(21-39(68)69)61-50(78)41(28(5)66)64-44(72)33(14-10-11-16-51)59-43(71)31(52)20-30-22-54-25-56-30/h7-9,12-13,22,25-28,31-37,40-41,65-66H,10-11,14-21,23-24,51-52H2,1-6H3,(H2,53,70)(H,54,56)(H,55,77)(H,57,67)(H,58,73)(H,59,71)(H,60,76)(H,61,78)(H,62,74)(H,63,75)(H,64,72)(H,68,69)

Relevant articles and documents

Enzymatic fragment condensation of side chain-protected peptides using subtilisin A in anhydrous organic solvents: A general strategy for industrial peptide synthesis

Herein, the enzymatic condensation of side chain-protected peptide fragments using subtilisin A in anhydrous organic solvents is described. A screening with dipeptide Cbz-Val-Xxx carboxamidomethyl esters with H-Xxx-Val-NH2 nucleophiles was performed, wherein Xxx stands for every (side chain-protected) amino acid residue. Finally, it was demonstrated that it is feasible to enzymatically condense larger peptide fragments (up to the 10-mer level) bearing multiple side chain-protecting groups with very high conversion.

Coordination abilities of neurokinin A and its derivative and products of metal-catalyzed oxidation

The classical tachykinins, substance P, neurokinin A and neurokinin B are predominantly found in the nervous system where they act as neurotransmitters and neuromodulators. Significantly reduced levels of these peptides were observed in neurodegenerative diseases and it may be suggested that this reduction may also result from the copper(II)-catalyzed oxidation. The studies of the interaction of copper(II) with neurokinin A and the copper(II)-catalyzed oxidation were performed. Copper(II) complexes of the neurokinin A (His-Lys-Thr-Asp-Ser-Phe-Val-Gly-Leu-Met-NH2) and acetyl-neurokinin A (Ac-His-Lys-Thr-Asp-Ser-Phe-Val-Gly-Leu-Met-NH2) were studied by potentiometric, UV-Vis (UV-visible), CD (circular dichroism) and EPR spectroscopic methods to determine the stoichiometry, stability constants and coordination modes in the complexes formed. The histidine residue in first position of the peptide chain of neurokinin A coordinates strongly to Cu(II) ion with histamine-like {NH2, NIm} coordination mode. With increasing of pH, the formation of a dimeric complex Cu2H2L2 was found but this dimeric species does not prevent the deprotonation and coordination of the amide nitrogens. In the Ac-neurokinin A case copper(II) coordination starts from the imidazole nitrogen of the His; afterwards three deprotonated amide nitrogens are progressively involved in copper coordination. To elucidate the products of the copper(II)-catalyzed oxidation of the neurokinin A and Ac-neurokinin A, liquid chromatography-mass spectrometry (LC-MS) method and Cu(II)/hydrogen peroxide as a model oxidizing system were employed.Oxidation target for both studied peptides is the histidine residue coordinated to the metal ions. Both peptides contain Met and His residues and are very susceptible on the copper(II)-catalyzed oxidation.

NEUROKININ &α AND &β, SYNTHESIS AND PHARMACOLOGICAL PROPERTIES

Two novel neuropeptides, neurokinin α and β, isolated from porcine spinal cord were chemically synthesized by solution method.The amino acid sequences proposed were confirmed to be correct and pharmacological properties of neurokinin peptides were studied